Review of Operations Directors’ Report Chairman’s Letter CEO’s Report Financial Report Shareholder Information 10 INTANGIBLE ASSETS AND GOODWILL (CONTINUED) SubB2M - which is in the research phase and therefore pre-revenue, was assessed for impairment using the replacement cost method. The cost approach reflects the amount that would be required currently to replace the service capacity of an asset less any wastage, obsolescence and costs of disposal. Management determined that no impairment was present at balance date. The assumptions used in the calculation of replacement cost resulted in an excess of fair value less cost of disposal over the carrying amount of 293%. 11 RIGHT OF USE ASSETS As at 30 June 2025 $ As at 30 June 2024 $ Right-of-use Asset – at cost 1,510,256 1,510,256 Accumulated depreciation (1,387,772) (1,194,196) 122,484 316,060 At the date of this report INOVIQ has one leased property. This lease was entered into by subsidiary Sienna Cancer Diagnostics Limited (Sienna). Sienna was acquired by INOVIQ on 28 July 2020. The following table provides a summary of the lease that represents the balance of the Right-of-use assets and Lease liability (see Note 13) on the Statement of Financial Position: Property Commencement Date Lease Term End Annual Increases Further Terms 23 Normanby Rd, Notting Hill, Victoria 7 June 2020 6 June 2026 3% N/A 12 TRADE AND OTHER PAYABLES As at 30 June 2025 $ As at 30 June 2024 $ Trade and other payables 346,233 626,394 Accruals 533,988 294,133 880,221 920,527 Trade and other payables are generally unsecured, interest free and with terms ranging from 7 to 30 days. 13 LEASE LIABILITY As at 30 June 2025 $ As at 30 June 2024 $ Current Lease liability 162,253 241,482 Non-current Lease liability – 162,253 Maturity analysis Less than 12 months 162,253 241,482 Greater than 12 months and less than 5 years – 162,253 Greater than 5 years – – 162,253 403,735 49 Annual Report 2025
RkJQdWJsaXNoZXIy MjE2NDg3